Patient and doctor views on cell therapies for advanced cancer
Part of Cancer clinical trials.
This study is a survey to learn about what patients and doctors think about newer cell-based cancer treatments (like CAR-T or TIL therapy). You will answer questions about your experiences and preferences, which will help guide future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a type of cancer called an advanced solid tumor (cancer that has spread or cannot be removed by surgery).
- You must have already had at least one round of cancer treatment (like chemotherapy, targeted therapy, or immunotherapy).
- Your daily activity level should be fairly good (able to take care of yourself, or needing some help but not bedridden).
- You must be able to read and answer a questionnaire, either alone or with assistance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This study looks at young people (40 or younger at diagnosis) with solid tumors in China. It aims to collect real-world information about their treatments and outcomes to find patterns that could help improve care.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.